Biomarkers in Alzheimer's disease

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 5, 2011, Pages 773-778

  Demarin, Vida ^a   Zavoreo, Iris ^a   Kes, Vanja Bašić ^a   Šimundić, Ana Marija ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Alzheimer's disease; biomarkers; neuroimaging

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA INTERNEXIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; ASPARTIC PROTEINASE; BETA SECRETASE; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; BILIVERDIN; BIOLOGICAL MARKER; CD40 ANTIGEN; EPITOPE; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GELATINASE B; HEME OXYGENASE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; ISOPROSTANE; NEUROFILAMENT PROTEIN; NEUROTRANSMITTER; PROGRANULIN; TAU PROTEIN; THREONINE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRAIN LEVEL; BRAIN SIZE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; EARLY DIAGNOSIS; ENTORHINAL CORTEX; ENZYME ACTIVITY; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL STATUS; GENE MUTATION; GUILLAIN BARRE SYNDROME; HIPPOCAMPAL VOLUME; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; LIPID PEROXIDATION; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMERIZATION; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY; STROKE; VOLUMETRY;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; HUMANS; MOLECULAR IMAGING; NERVOUS SYSTEM;

EID: 79954565817     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.139     Document Type: Review

References (49)

1. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K. Mild cognitive impairment. Lancet 2006;367:1262-70.
2. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13. (Pubitemid 37162569)
3. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blen-now K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008;4:38-48.
4. Clifford J, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Wei-ner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2001;9:1474-794.
5. Consensus Report of the Working Group on Molecular and Bio-chemical Markers of Alzheimer's Disease: the Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-16.
6. Morris JC, Price AL. Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101-18. (Pubitemid 33063515)
7. Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Eds-bagge M, Wikkelsø C Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of ref-erence values. Clin Chem 2001;47:1776-81. (Pubitemid 32881189)
8. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59: 512-9. (Pubitemid 43358072)
9. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9. (Pubitemid 46667813)
10. Hasegawa M. Biochemistry and molecular biology of tauopa-thies. Neuropathology 2006;26:484-90.
11. Buerger K, Ewers M, Pirttilä T, Zinkowski R, AlafuzoffI, Tei-pel SJ. CSF phosphorylated tau protein correlates with neocor-tical neurofibrillary pathology in Alzheimer's disease. Brain 2006;129:3035-41. (Pubitemid 44684523)
12. Buerger K, Alafuzoff I, Ewers M, Pirttilä T, Zinkowski R, Hampel H. No correlation between CSF tau protein phospho-rylated at threonine 181 with neocortical neurofibrillary pathol-ogy in Alzheimer disease. Brain 2007;130:82.
13. Ewers M, Buerger K, Teipel SJ, Scheltens P, Schröder J, Zin-kowski RP. Multicentre assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007;69: 2205-12. (Pubitemid 350294675)
14. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-34. (Pubitemid 43238346)
15. Zhong Z, Ewers M, Teipel S, Bürger K, Wallin K, Blennow K. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry 2007;64:718-26. (Pubitemid 46878672)
16. Kuhle J, Regeniter A, Leppert D, Mehling M, Kappos L, Lind-berg RL, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010;220:114-9.
17. Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zette-berg H, Siemers E, et al. A novel A-ß isoform pattern in CSF reflects 7-secretase inhibition in Alzheimer disease. Alzheimers Res Ther 2010;1:2-7.
18. Irizarry MC. Biomarkers of Alzheimer disease in plasma. Neurology 2004;1:226-34. (Pubitemid 46591884)
19. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study Lancet Neurol 2006; 5:655-60. (Pubitemid 44062411)
20. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik JR. Association of low plasma Abeta 42/Abeta40 ratios with increased imminent risk for mild cognitive impair-ment and Alzheimer disease. Arch Neurol 2007;64:354-62. (Pubitemid 46425689)
21. Sleegers K, Brouwers N, Van Broeckhoven C Role of progra-nulin as a biomarker for Alzheimer disease. Biomark Med 2010;4:37-50.
22. Cheng X, Yang L, He P, Li R, Shen Y. Differential activation of TNF receptors distinguishes between brains from Alzheimer disease and non-demented patients. J Alzheimers Dis 2010;19: 621-30.
23. Zhang Lj, Xiao Y, Qi Xl. Cholinesterase activity and mRNA level of nicotinic acetylcholine receptors (α and ß subunits) in blood of elderly Chinese diagnosed as Alzheimer disease. J Alzheimers Dis 2010;19:849-58.
24. Mueller C, Zhou W, Vanmarter A, Heiby M, Magaki S, Ross MM, et al. The heme degradation pathaway is a promising serum biomarker source for the early detection of Alzheimer disease. J Alzhemiers Dis 2010;19:1081-91.
25. Fehlbaum-Berdeley P, Jarrige le Prado AC, Pallares D, Carrerre J. Toward an Alzheimer's disease prognosis via high-resolution blood gene expression. Alzheimers Dement 2010;6;25-38.
26. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP. VEGF genetic variability is associated with increased risk for devel-oping Alheimer's disease. J Neurol Sci 2009;283:66-9.
27. Jack CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403. (Pubitemid 29190530)
28. Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D. Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly Neu-roimage 2005;25:783-92. (Pubitemid 40461717)
29. Ewers M, Teipel SJ, Dietrich O, Schönberg SO, Jessen F, Heun R. Multicenter assessment of reliability of cranial MRI. Neu-robiol Aging 2006;27:1051-9. (Pubitemid 43850650)
30. Hsu YY, Schuff N, Du AT, Mark K, Zhu X, Hardin D. Com-parison of automated and manual MRI volumetry of hippocam-pus in normal aging and dementia. J Magn Reson Imaging 2002;16:305-10. (Pubitemid 34920430)
31. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hän-ninen T, Laakso MP. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004;25:303-10. (Pubitemid 38220965)
32. Xu Y, Jack CR, O'Brien PC, Kokmen E, Smith GE, Ivnik RJ. Usefulness of MRI measures of entorhinal cortex versus hip-pocampus in AD. Neurology 2000;54:1760-7. (Pubitemid 30428402)
33. Ashburner J, Friston FJ. Voxel-based morphometry: the meth-ods. Neuroimage 2000;11:805-21.
34. Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC. Global and local gray matter loss in mild cog-nitive impairment and Alzheimer's disease, Neuroimage 2004; 23:708-16. (Pubitemid 39370621)
35. Teipel SJ, Born C, Ewers M, Bokde AL, Reiser MF, Möller HJ. Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neu-roimage 2007;38:13-24. (Pubitemid 47429985)
36. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy Cereb Cortex 2005;15:995-1001. (Pubitemid 40848068)
37. Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe: a study of a five-year change. Neurology 2004;62:433-8. (Pubitemid 38200856)
38. Celone KA, Calhoun VD, Dickerson VB, Atri A, Chua EF Miller SL. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent compo-nent analysis. J Neurosci 2006;26:10222-31. (Pubitemid 44527415)
39. Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study Hum Brain Mapp 2005;26:231-9. (Pubitemid 41759880)
40. Demarin V, Basić Kes V, Morović S, Zavoreo I. Evaluation of aging vs dementia by means of neurosonology J Neurol Sci 2009;283:9-12.
41. Zavoreo I, Kes VB, Morović S, Serić V, Demarin V Breath holding index in detection of early cognitive decline. J Neurol Sci 2010;299:116-9.
42. Teipel SJ, Stahl S, Dietrich O, Schoenberg SO, Perneczky R, Bokde AL. Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage 2007;34:985-95. (Pubitemid 46394457)
43. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res 2006;3:161-70.
44. Eckelman WC. Imaging of muscarinic receptors in the central nervous system. Curr Pharm Des 2006;12:3901-13. (Pubitemid 44560701)
45. Teipel SJ, Drzezga A, Bartenstein P, Möller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-overtrial. Psychopharmacology (Berl) 2006; 187:86-94. (Pubitemid 43876920)
46. Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's dis-ease. Neurobiol Aging 2007;28:1062-9.
47. Bouwman FH, Schoonenboom SN, van der Flier VN, van Elk EJ, Kok A, Barkhof F. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007;28:1070-4. (Pubitemid 46635910)
48. de Jong D, Jansen RW, Kremer BP, Verbeek MM. Cerebrospi-nal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci 2006;28:755-8. (Pubitemid 44148364)
49. Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H. Amyloid beta peptide ratio 42/40 but not A beta 42 corre-lates with phospho-Tau in patients with low-and high-CSF A beta 40 load. J Neurochem 2007;101:1053-9. (Pubitemid 46683864)